WO2008048691A3 - Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders - Google Patents

Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders Download PDF

Info

Publication number
WO2008048691A3
WO2008048691A3 PCT/US2007/022413 US2007022413W WO2008048691A3 WO 2008048691 A3 WO2008048691 A3 WO 2008048691A3 US 2007022413 W US2007022413 W US 2007022413W WO 2008048691 A3 WO2008048691 A3 WO 2008048691A3
Authority
WO
WIPO (PCT)
Prior art keywords
leptin
lipectomy
post
fat deposition
ectopic fat
Prior art date
Application number
PCT/US2007/022413
Other languages
French (fr)
Other versions
WO2008048691A2 (en
Inventor
Howard E Greene
Andrew A Young
Original Assignee
Amylin Pharmaceuticals Inc
Howard E Greene
Andrew A Young
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc, Howard E Greene, Andrew A Young filed Critical Amylin Pharmaceuticals Inc
Publication of WO2008048691A2 publication Critical patent/WO2008048691A2/en
Publication of WO2008048691A3 publication Critical patent/WO2008048691A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Leptin, leptin analogs, leptin derivatives, and other leptin agonists are used to treat subjects with post-lipectomy ectopic fat deposition and associated metabolic abnormalities or disorders. Such leptin, leptin analogs, derivatives, and other leptin agonists are also used in the preparation of medicaments for treating or preventing ectopic fat deposition and associated metabolic abnormalities or disorders in such subjects. Such ectopic fat deposition and metabolic abnormalities conditions or disorders include, but are not limited to, hepatic steatosis, hypertriglyceridemia, dyslipidemia, cardiovascular disease, insulin-resistance, and diabetes mellitus.
PCT/US2007/022413 2006-10-18 2007-10-18 Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders WO2008048691A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85281106P 2006-10-18 2006-10-18
US60/852,811 2006-10-18

Publications (2)

Publication Number Publication Date
WO2008048691A2 WO2008048691A2 (en) 2008-04-24
WO2008048691A3 true WO2008048691A3 (en) 2008-07-24

Family

ID=39309590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022413 WO2008048691A2 (en) 2006-10-18 2007-10-18 Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders

Country Status (1)

Country Link
WO (1) WO2008048691A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143380A2 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2009149379A2 (en) * 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
EP2352510A4 (en) 2008-11-04 2012-08-29 Neurotez Inc Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
WO2011036665A2 (en) * 2009-09-22 2011-03-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Akt/mtorc1 pathway activators for use in increasing liver regeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018833A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
WO2003034996A2 (en) * 2001-10-22 2003-05-01 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018833A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
WO2003034996A2 (en) * 2001-10-22 2003-05-01 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
US20050020496A1 (en) * 2001-10-22 2005-01-27 Amgen Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D. B. HAUSMAN ET AL: "Compensatory Growth of Adipose Tissue After Partial Lipectomy: Involvement of Serum Factors", EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 229, 2004, pages 512 - 520, XP002478543 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; October 1998 (1998-10-01), MATARASSO A ET AL: "The impact of liposuction on body fat", XP002478545, Database accession no. EMB-1998345535 *
E. D. JAVOR ET AL: "Long-Term Efficacy of Leptin Replacement in Patients with Generalized Lipodystrophy", DIABETES, vol. 54, July 2005 (2005-07-01), pages 1994 - 2002, XP002478542 *
PLASTIC AND RECONSTRUCTIVE SURGERY 199810 US, vol. 102, no. 5, October 1998 (1998-10-01), pages 1686 - 1689, ISSN: 0032-1052 *
R.V. WEBER ET AL: "Subcutaneous lipectomy causes a metabolic syndrome in hamsters", AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, vol. 279, 2000, pages 936 - 943, XP002478544 *

Also Published As

Publication number Publication date
WO2008048691A2 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
PL2211842T3 (en) An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
WO2010138899A3 (en) Trimethylamine-containing compounds for diagnosis and prediction of disease
WO2008108958A3 (en) Benzimidazole derivatives and methods of use thereof
WO2009055331A3 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
WO2008070692A3 (en) Bicyclic compounds and use as antidiabetics
ZA200706294B (en) Roflumilast for the treatment of diabetes mellitus
WO2011028947A3 (en) Heterocyclic compounds for the inhibition of pask
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
WO2010049678A3 (en) Treatment of energy utilization diseases
WO2007124461A8 (en) Glp-1 compounds
WO2010048207A3 (en) Aryl gpr120 receptor agonists and uses thereof
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
IL186200A (en) Use of amylin and amylin agonists, analogs and derivatives for the preparation of medicaments for treating psychiatric diseases
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
WO2008153788A3 (en) Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
WO2012054526A3 (en) Chemosensory receptor ligand-based therapies
PL2288364T3 (en) Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
WO2011161427A3 (en) Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2012019188A3 (en) Methods and compositions for the inhibition of fructokinase
WO2012119046A3 (en) Heterocyclic compounds for the inhibition of pask
WO2016060517A3 (en) Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
ZA200904281B (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07861474

Country of ref document: EP

Kind code of ref document: A2